

Supplementary Table 1: Patient Demographics

Factor	All NSCLC	Lung ADCA	Lung SCCA	Other
<i>N</i>	73	54 (74%)	15 (21%)	4 (5%)
Age	67.3	66.5	69.1	71.8
% Male	49	43	67	75
Race				
White	64 (88)	47 (87)	13 (86)	4 (100)
Asian	6 (8)	5 (9)	1(7)	0
Other	3 (4)	2 (4)	1 (7)	0
Smoking				
Current	20 (27)	15 (28)	5 (33)	0
Former	45 (62)	33 (61)	10 (67)	2 (50)
Never	8 (11)	6 (11)	0	2 (50)
Pack Years	29.9	27.9	41.1	13.8
Size (cm)	2.78	2.69	3.06	2.93
Stage				
1A	25 (34)	19 (35)	6 (40)	0
1B	23 (32)	18 (33)	3 (20)	2 (50)
2A	10 (14)	7 (13)	2 (13)	1 (25)
2B	4 (5)	2 (4)	1 (7)	1 (25)
3A	10 (14)	7 (13)	3 (20)	0
4	1 (1)	1 (2)	0	0

Supplementary Table 2: Immune Cell Markers

Antigen	Label	Clone	ul/test	Company	Catalog #
CD14	BUV395	MφP9	5	BD	563561
CD16	BV605	3G8	5	BD	563172
CD3	PE-CF594	UCHT1	5	BD	562280
CD4	BUV395	SK3	5	BD	563550
IL17A	PE	N49-653	20	BD	560486
IFNγ	FITC	B27	1	BD	554700
CD127	BV786	HIL-7R-M21	5	BD	563324
CD19	BUV737	SJ25C1	5	BD	564303
CD15	BV786	HI98	5	BD	563838
HLA-DR	BUV661	G46-6	5	BD	565073
CD4	BV605	OKT4	5	Biologend	317438
CD45	AlexaFluor700	HI30	1	Biologend	304024
CD66b	PE	G10F5	5	Biologend	305106
CD68	APC	Y1/82A	5	Biologend	333810
CD274 (PDL1)	PE-Cy7	29E.2A3	5	Biologend	329718
CD33	BV421	WM53	5	Biologend	303416
CD4	BV605	RPA-T4	5	Biologend	317438
CD25	BV421	BC96	5	Biologend	302630
TCR$\gamma\delta$	APC	B1.1	5	Biologend	331212
CD8	BV510	RPA-T8	5	Biologend	301048
CD8	FITC	RPA-T8	2	Biologend	301006
CD56	PE	HCD56	5	Biologend	318306
CD20	BV421	2H7	5	Biologend	302330
NKG2D	PE-Cy7	1D11	5	Biologend	320812
CCR7	PE-Cy7	G043H7	5	Biologend	353226
CD45RA	APC	HI100	5	Biologend	304112
CD69	BV605	FN50	5	Biologend	310938
PD1	BV421	EH12.2H7	5	Biologend	329920
CD326 (EpCAM)	FITC	9C4	5	Biologend	324204
CD11b	BV650	ICRF44	5	Biologend	301336
IL22	PE-Cy7	22URTI	5	eBioscience	25-7229-42
CD19	PerCPCy5.5	HIB19	5	eBioscience	45-0199-42
FVD	APC-ef780	-	0.2	eBioscience	65-0865-14
TIM3	PE	344823	5	R&D Systems	FAB2365P

Supplementary Table 3: Unpaired t-tests for lung vs. tumor and L-ADCA vs. L-SCCA

% of	Cell population	Lung vs. Tumor	ADCA vs SCCA
% live	CD45	0.82241	0.07023
% live	EpCAM	0.01065	0.92376
% CD45	CD3	0.00000	0.99500
% CD45	CD4	0.00001	0.24897
% CD45	CD8	0.00016	0.10618
% CD45	Tgd	0.65118	0.92503
% CD45	NK	0.00025	0.85798
% CD45	NKT	0.00991	0.34630
% CD45	Bcells	0.00000	0.56647
% CD45	Mac	0.00000	0.01975
% CD45	Mono	0.68578	0.71318
% CD45	CD14-CD33+	0.87744	0.27477
% CD45	PMN	0.37325	0.03282
% gdT	Tgd IL17A	0.00407	0.85899
% gdT	Tgd IFNg	0.85221	0.85580
% gdT	Tgd IL22	0.00849	0.13732
% CD4	CD4+ IL17A	0.05864	0.03528
% CD4	CD4+IL22	0.42312	0.31931
% CD4	CD4+IL17A+IL22+	0.01718	0.31057
% CD4	CD4+IFNg	0.00035	0.04707
% CD4	Treg	<0.00001	0.00006
% CD4	CD4EM	0.24833	0.20101
% CD4	CD4CM	0.16730	0.73166
% CD4	CD4naive	0.00543	0.41214
% CD4	CD4EMRA	0.00379	0.47215
% CD4	CD4+ CD69	0.60107	0.07469
% CD4	CD4+ PD1	0.00000	0.00253
% CD4	CD4+ TIM3	0.00016	0.11155
% CD4	CD4+ PD1-TIM3-	0.00000	0.02700
% CD4	CD4+ PD1+TIM3-	0.00012	0.01946
% CD4	CD4+ PD1+TIM3+	0.00000	0.44402
% CD4	CD4+ PD1-TIM3+	0.81601	0.25677
% CD8	CD8+IFNg	0.33900	0.98888
% CD8	CD8EM	0.00000	0.01226
% CD8	CD8CM	0.07400	0.86100
% CD8	CD8naive	0.21348	0.70970
% CD8	CD8EMRA	0.00000	0.00643
% CD8	CD8+ CD69	0.18627	0.12426
% CD8	CD8 PD1	0.00000	0.01085
% CD8	CD8+ TIM3	0.00000	0.66851
% CD8	CD8+ PD1-TIM3-	0.00000	0.01559
% CD8	CD8+ PD1+TIM3-	0.00377	0.01881
% CD8	CD8+ PD1+TIM3+	0.00000	0.47425
% CD8	CD8+ PD1-TIM3+	0.32673	0.58201
MFI	CD4+ CD69	0.63653	0.24495
MFI	CD4+ PD1	0.00006	0.00952
MFI	CD4+TIM3	0.00184	0.42447
MFI	CD8+CD69	0.00030	0.19333
MFI	CD8+PD1	0.00000	0.02811
MFI	CD8+ TIM3	0.00000	0.90053
MFI	NKT NKG2D	0.00047	0.72978
MFI	NK NKG2D	0.44371	0.39137

MFI	Tgd NKG2D	0.00899	0.27486
MFI	total PD-L1	0.02706	0.16392
MFI	PMN PD-L1	0.00346	0.04823
MFI	Mac PD-L1	0.13175	0.67825
MFI	Mono PD-L1	0.01229	0.01020
MFI	CD45- PD-L1	0.04190	0.09140
MFI	EpCAM PD-L1	0.00202	0.01953

Supplementary Table 4: Unpaired t-tests for lung vs. tumor and L-ADCA vs. L-SCCA (all data expressed as % of CD45)

% of	Cell population	Lung vs Tumor	ADCA vs SCCA
% CD45	CD3	0.00000	0.99500
% CD45	CD4	0.00001	0.24897
% CD45	CD8	0.00016	0.10618
% CD45	Tgd	0.65118	0.92503
% CD45	NK	0.00025	0.85798
% CD45	NKT	0.00991	0.34630
% CD45	Bcells	0.00000	0.56647
% CD45	Mac	0.00000	0.01975
% CD45	Mono	0.68578	0.71318
% CD45	CD14-CD33+	0.87744	0.27477
% CD45	PMN	0.37325	0.03282
% CD45	Tgd IL17	0.00007	0.63034
% CD45	Tgd IFNg	0.00018	0.39253
% CD45	Tgd IL22	0.00048	0.37731
% CD45	CD4+ IL17	0.00002	0.06999
% CD45	CD4+IL22	0.00019	0.15406
% CD45	CD4+IL17+IL22+	0.00025	0.16325
% CD45	CD4+IFNg	0.20615	0.05323
% CD45	Treg	<0.00001	0.14309
% CD45	CD4EM	0.00001	0.64308
% CD45	CD4CM	0.03315	0.67581
% CD45	CD4naive	0.47011	0.44593
% CD45	CD4EMRA	0.57728	0.59177
% CD45	CD4+ CD69	0.03388	0.12500
% CD45	CD4+ PD1	0.00000	0.22081
% CD45	CD4+ TIM3	0.00004	0.18678
% CD45	CD4+ PD1-TIM3-	0.42348	0.14813
% CD45	CD4+ PD1+TIM3-	0.00000	0.54021
% CD45	CD4+ PD1+TIM3+	0.00000	0.70350
% CD45	CD4+ PD1-TIM3+	0.09197	0.34784
% CD45	CD8+IFNg	0.00510	0.00699
% CD45	CD8EM	0.00000	0.00737
% CD45	CD8CM	0.02628	0.40778
% CD45	CD8naive	>0.99999	0.21574
% CD45	CD8EMRA	0.13812	0.37237
% CD45	CD8+ CD69	0.00503	0.58720
% CD45	CD8 PD1	0.00000	0.00388
% CD45	CD8+ TIM3	0.00001	0.36818
% CD45	CD8+ PD1-TIM3-	0.48928	0.97415
% CD45	CD8+ PD1+TIM3-	0.00000	0.00079
% CD45	CD8+ PD1+TIM3+	0.00000	0.18855

% CD45	CD8+ PD1-TIM3+	0.01149	0.94173
---------------	----------------	---------	---------

Supplementary Table 5: Unpaired t-tests for lung vs. tumor and L-ADCA vs. L-SCCA (all data expressed as % live cells)

% live	Cell population	Lung vs. Tumor	ADCA vs SCCA
% live	CD45	0.82241	0.07023
% live	EpCAM	0.01065	0.92376
% live	CD3	0.00001	0.6991
% live	CD4	0.00005	0.50106
% live	CD8	0.00036	0.08976
% live	Tgd	0.77885	0.78054
% live	NK	0.00016	0.64302
% live	NKT	0.01015	0.17846
% live	Bcells	0.00000	0.40496
% live	Mac	0.00000	0.04052
% live	Mono	0.51530	0.95403
% live	CD14-CD33+	0.84399	0.28161
% live	PMN	0.43756	0.00984
% live	Tgd IL17	0.00008	0.74648
% live	Tgd IFNg	0.00046	0.60967
% live	Tgd IL22	0.00040	0.31897
% live	CD4+ IL17	0.00002	0.09807
% live	CD4+IL22	0.00022	0.18593
% live	CD4+IL17+IL22+	0.00067	0.19046
% live	CD4+IFNg	0.28961	0.10198
% live	Treg	0.00000	0.0987
% live	CD4EM	0.00010	0.77226
% live	CD4CM	0.02255	0.66526
% live	CD4naive	0.54511	0.42745
% live	CD4EMRA	0.63671	0.61308
% live	CD4+ CD69	0.05484	0.17963
% live	CD4+ PD1	0.00000	0.20101
% live	CD4+ TIM3	0.00010	0.1636
% live	CD4+ PD1-TIM3-	0.57364	0.16856
% live	CD4+ PD1+TIM3-	0.00000	0.48527
% live	CD4+ PD1+TIM3+	0.00000	0.56738
% live	CD4+ PD1-TIM3+	0.06542	0.38413
% live	CD8+IFNg	0.01215	0.01252
% live	CD8EM	0.00000	0.00311
% live	CD8CM	0.02532	0.3698


% live	CD8naive	>0.999999	0.10423
% live	CD8EMRA	0.10679	0.70531
% live	CD8+ CD69	0.00701	0.61274
% live	CD8 PD1	0.00000	0.00753
% live	CD8+ TIM3	0.00001	0.43539
% live	CD8+ PD1-TIM3-	0.34422	0.87999
% live	CD8+ PD1+TIM3-	0.00002	0.00285
% live	CD8+ PD1+TIM3+	0.00000	0.21704
% live	CD8+ PD1-TIM3+	0.01421	0.9417


Supplementary Table 6: Linear regression associating cell composition and MFI with control, tumor size, and pack years (PY) smoking

Population	Control coefficients	Size coefficients	PY coefficients	Control p-value	Size p-value	PY p-value
CD45	0.3312 ± 0.09231	1.759 ± 1.115	0.07386 ± 0.07148	0.0006	0.1192	0.3050
CD3	0.2014 ± 0.09119	-1.737 ± 1.245	0.1884 ± 0.09356	0.0307	0.1675	0.0481
CD4	0.3197 ± 0.1043	-1.223 ± 0.7578	0.04572 ± 0.05098	0.0031	0.1113	0.3729
CD8	0.1607 ± 0.07470	-0.6643 ± 0.7019	0.09401 ± 0.04513	0.0350	0.3472	0.0410
γδ T	0.8634 ± 0.1752	0.03111 ± 0.07434	0.006777 ± 0.004743	< 0.0001	0.6770	0.1576
NK	0.8407 ± 0.2065	-0.2598 ± 0.1545	0.002702 ± 0.01249	0.0001	0.0973	0.8294
NK-T	1.524 ± 0.2342	0.05241 ± 0.1289	0.01434 ± 0.009610	< 0.0001	0.6857	0.1404
B	0.003692 ± 0.02025	-0.06123 ± 0.3436	0.01480 ± 0.02668	0.8559	0.8591	0.5811
Macrophage	0.1795 ± 0.2236	-1.050 ± 0.8958	-0.09606 ± 0.05823	0.4249	0.2452	0.1039
Monocyte	0.1753 ± 0.06969	0.9495 ± 0.4745	-0.03354 ± 0.03239	0.0144	0.0498	0.3044
CD14 ⁺ CD33 ⁺	0.3351 ± 0.1210	-0.8341 ± 1.164	-0.04670 ± 0.09277	0.0076	0.4767	0.6167
Neutrophil	0.08579 ± 0.1291	3.626 ± 0.8827	-0.001736 ± 0.06593	0.5086	0.0001	0.9791
EpCAM	0.1406 ± 0.1079	-1.378 ± 0.8848	0.02942 ± 0.06869	0.2013	0.1271	0.6707
γδ T-IL17	-38.84 ± 84.80	0.01561 ± 0.3021	-0.01855 ± 0.02365	0.6486	0.9589	0.4358
γδ T-IFNγ	0.4196 ± 0.1279	-1.886 ± 1.482	0.004953 ± 0.1179	0.0017	0.2081	0.9666
γδ T-IL22	0.03459 ± 0.03067	0.7857 ± 0.3331	0.01791 ± 0.02777	0.2645	0.0221	0.5219
CD8-IFNγ	0.1734 ± 0.1380	1.969 ± 2.918	-0.1019 ± 0.1107	0.2148	0.5215	0.3616
Th17	0.2303 ± 0.09434	0.004461 ± 0.2326	-0.009093 ± 0.01536	0.0174	0.9848	0.5560
Th22	0.3134 ± 0.1925	-0.1063 ± 0.1017	0.003830 ± 0.008164	0.1093	0.3006	0.6410
CD4 ⁺ IL17A ⁺ IL22 ⁺	0.2747 ± 0.06858	-0.03911 ± 0.06193	-4.025e-005 ± 0.0048	0.0002	0.5305	0.9934
Th1	0.6169 ± 0.1041	-3.256 ± 1.454	0.05526 ± 0.09883	< 0.0001	0.0286	0.5780
Treg	0.08373 ± 0.04710	1.305 ± 0.6229	0.08739 ± 0.04606	0.0802	0.0402	0.0623
CD4EM	0.8804 ± 0.1128	0.2945 ± 0.8164	-0.02053 ± 0.06708	< 0.0001	0.7201	0.7608
CD4CM	0.7811 ± 0.1126	-0.2779 ± 0.5985	-0.0009962 ± 0.0444	< 0.0001	0.6443	0.9822
CD4Naive	1.066 ± 0.1698	-0.04392 ± 0.09992	-0.006663 ± 0.00733	< 0.0001	0.6620	0.3675
CD4EMRA	1.007 ± 0.08827	0.7829 ± 0.7691	0.02836 ± 0.05752	< 0.0001	0.3133	0.6240
CD8EM	0.4510 ± 0.1445	1.688 ± 1.240	0.1416 ± 0.08856	0.0029	0.1790	0.1156
CD8CM	1.461 ± 0.1185	-0.4273 ± 0.3619	-0.01774 ± 0.02651	< 0.0001	0.2429	0.5061
CD8Naive	1.040 ± 0.1042	-0.1031 ± 0.09820	-0.01404 ± 0.006890	< 0.0001	0.2983	0.0464
CD8EMRA	0.5094 ± 0.1572	-1.268 ± 1.219	-0.1385 ± 0.08629	0.0021	0.3026	0.1141
CD8CD69	0.8705 ± 0.05154	-0.3617 ± 2.258	0.02389 ± 0.1777	< 0.0001	0.8733	0.8936
CD8PD1	0.6092 ± 0.1076	0.4014 ± 1.653	0.2259 ± 0.1254	< 0.0001	0.8091	0.0773
CD8TIM3	0.06222 ± 0.03224	0.8838 ± 1.039	0.1116 ± 0.08032	0.0589	0.3988	0.1704
CD4CD69	0.9283 ± 0.05027	-3.066 ± 2.062	-0.1545 ± 0.1621	< 0.0001	0.1432	0.3450
CD4PD1	0.5593 ± 0.09301	3.356 ± 1.639	0.2460 ± 0.1271	< 0.0001	0.0457	0.0583
CD4TIM3	0.2042 ± 0.04277	1.251 ± 0.6378	-0.02327 ± 0.05126	< 0.0001	0.0552	0.6517
MFI						
NK-T NKG2D	1.105 ± 0.1120	-6.791 ± 8.921	-0.3963 ± 0.7181	< 0.0001	0.4497	0.5832
NK NKG2D	0.9211 ± 0.1064	2.864 ± 5.806	-0.5888 ± 0.4585	< 0.0001	0.6237	0.2044
γδ T NKG2D	0.9805 ± 0.1651	-12.03 ± 6.655	-0.5203 ± 0.5428	< 0.0001	0.0763	0.3421
CD8CD69	0.8375 ± 0.08911	-18.63 ± 24.99	-1.500 ± 1.802	< 0.0001	0.4593	0.4087
CD8PD1	0.09831 ± 0.07068	42.81 ± 22.28	4.469 ± 1.666	0.1700	0.0598	0.0096
CD8TIM3	0.1390 ± 0.04129	3.801 ± 7.113	1.304 ± 0.5296	0.0014	0.5952	0.0170
CD4CD69	0.9715 ± 0.07771	-9.670 ± 15.65	-0.9069 ± 1.126	< 0.0001	0.5393	0.4243
CD4PD1	0.2020 ± 0.06215	95.53 ± 23.22	2.079 ± 2.049	0.0020	0.0001	0.3149
CD4TIM3	0.1984 ± 0.04289	9.819 ± 4.906	0.6699 ± 0.3852	< 0.0001	0.0504	0.0877
PMN PDL1	0.3927 ± 0.07647	-2.603 ± 9.524	0.03010 ± 0.8210	< 0.0001	0.7856	0.9709
Mac PDL1	0.6949 ± 0.1321	-31.74 ± 48.54	-0.1372 ± 4.016	< 0.0001	0.5159	0.9729
Mono PDL1	0.6166 ± 0.08614	4.838 ± 26.21	0.1803 ± 2.103	< 0.0001	0.8542	0.9320
CD45 ⁺ PDL1	0.4836 ± 0.05650	7.593 ± 11.20	0.3806 ± 0.8961	< 0.0001	0.5003	0.6725
EpCAM PDL1	0.06115 ± 0.04264	-10.63 ± 14.34	1.630 ± 1.066	0.1588	0.4627	0.1334


Supplementary Table 7: Immune cell populations with significant differences by clinical stage (Two-Way ANOVA)

	Cell population	stage	NSCLC	ADCA
MFI	CD4+ PD1	1a vs. 3/4	<0.0001	<0.0001
MFI	total PD-L1	1a vs. 3/4	<0.0001	<0.0001
MFI	Mono PD-L1	1a vs. 3/4	<0.0001	0.0006
MFI	CD8+ PD1	1a vs. 3/4	ns	0.0013
MFI	Mac PD-L1	1a vs. 3/4	ns	0.0056







Supplementary Figure 2. Representative dot plots demonstrating gating controls. Experimental sample (multicolor stain, left), fluorescence minus one control (FMO, right) for lymphocyte panels, left; intracellular panel, middle; and myeloid panel, right; are displayed. The unstimulated control (only intracellular panel) was used for gating of cytokines (IL17, IFN γ , IL22). Median fluorescence intensity (MFI) was used for functional markers (CD69, PD1, TIM3, PDL1; FMO=dotted line, multicolor stain=black line; middle panel, bottom).




Supplementary Figure 3. a) CD45⁺ staining of tumor and matched normal tissue for representative cases from NSCLC (smoker), NSCLC (non-smoker), urinary bladder cancer, and ovarian carcinoma. Despite identical staining protocols, the percentage of cells staining for CD45 varies by case and tissue. Red arrow depicts auto-fluorescent macrophages present in tumor and normal tissue from NSCLC smoker cases but not seen in other cases. b) Representative dot plots for lung and tumor displaying fixable viability dye (FVD) staining as contour (top) and pseudocolor (bottom). Contour plots were used for gating on live cells (FVD negative). c) FVD and propidium iodide (PI) co-staining were initially performed on lung and tumor single cell suspensions to examine different methods to discriminate live from dead cells (N=6). FVD and PI define similar live cell populations. FVD negative gated cells (blue) overlay on PI staining (red). FVD was used throughout the study to discriminate live from dead cells. d) Tabulation of live cells (FVD negative) for lung and tumor specimens (N=73), P=NS. e) Major cell populations were backgated on FVD gate (left panels) and CD45 gate (right panels) to confirm live/dead gating (two representative lung and tumor specimens).




Supplementary Figure 4. Receiver Operating Characteristic (ROC) Curves showing discrimination ability of cell subset markers to differentiate tumor from normal lung tissue (top) and L-ADCA from L-SCCA (bottom). Solid lines indicate cell types that are more extreme in tumor vs. lung tissue (or L-ADCA vs. L-SCCA), and dotted lines indicate cell types that are more extreme in lung tissue vs. tumor (or L-SCCA vs. L-ADCA). The cell type marked “other” represents the difference between the total cell composition of the subset and 100% (i.e. the fraction otherwise not accounted for).




Supplementary Figure 5. The CD4⁺CD25⁺FoxP3⁺ and CD4⁺CD25⁺CD127^{lo} definitions of Tregs were compared on a set of N=8 NSCLC specimens. a) Representative gating of FoxP3 (top) and CD25/CD127 (bottom) depicting FMO controls (left) and tumor and lung (right). b) Tabulation of Tregs shows that both methods identified a similar number of cells as Tregs. The CD25⁺CD127^{lo} methods was used during the remainder of the study to quantify Tregs.





Supplementary Figure 6. Comparison of immune cell composition in lung tissue (white) and NSCLC tissue (green) for all cell populations analyzed. Data are presented as % live, %CD45⁺, % parent, or median fluorescence intensity (MFI), as indicated. Statistical analysis for each comparison is provided in Supplementary Table 3.




Supplementary Figure 7. Comparison of immune cell composition in L-ADCA (blue) and L-SCCA (red) specimens for all cell populations analyzed. Data are presented as % live, % CD45+, % parent or median fluorescence intensity (MFI), as indicated. Statistical analysis for each comparison is provided in Supplementary Table 3.




Supplementary Figure 8. Tabulation of immune cell content in non-adjacent lung tissue (white bars), NSCLC tissue (green bars), L-ADCA (blue bars) and L-SCCA (red bars) as measured by flow cytometry. Data are expressed as % of CD45+ cells (a and c) and as % of live cells (b and d).




Supplementary Figure 9. Quantile plots comparing euclidean distance within the appropriate geometry for compositional data (see compositions package in R) of patient samples between ADCA (horizontal axis) and SCCA (vertical axis) for CD45⁺ subsets (black), CD3⁺ subsets (red), and CD4⁺ subsets (green). The strong deviation of CD4⁺ subsets away from the line indicate its higher levels of heterogeneity compared to SCCA. On the raw scale, the increased heterogeneity appears to be driven by a small fraction of the cases. On the relative scale, the deviation can be seen to occur throughout the entire distribution.



Supplementary Figure 10. PDL1 expression (MFI) from lung tissue and lung tumor for a) all cells, b) neutrophils, c) macrophages, d) monocytes) CD45⁻ cells, and f)Epcam⁺ cells as measured by flow cytometry. g) Tabulation of PDL1 expression by cell type. Bars +/- SEM. *P<0.05 (student's t-test).



Supplementary Figure 11. Representative dot plots for myeloid derived suppressor cell (MDSC) gating. a) M-MDSC (CD11b⁺CD14⁺HLA-DR^{lo}) and b) the neutrophil lineage (CD66b⁺/HLA-DR⁻) from healthy volunteer donor blood (far left), NSCLC patient blood (left), tumor tissue (right) and lung tissue (far right). Tabulation of c) M-MDSC and d) CD66b⁺HLA-DR⁻ cells. e) CD66b and CD15 identify an equivalent number of cells as neutrophils (N=16). f) Tabulation of neutrophils located in the low density fraction following sucrose density gradient centrifugation for blood from healthy donor volunteers (N=6) and NSCLC patients (N=8). *P<0.05.



Supplementary Figure 12. a) Tabulation of CD14-CD33⁺ cells in lung tissue and tumor tissue. Linear correlation of CD14-CD33⁺ cells and b) CD8⁺ cells, c) CD4⁺ cells, and d) tumor tissue. P=NS for each regression.